The global liquid biopsy market is projected to experience remarkable growth, with an estimated revenue of USD 1,538.3 million in 2023. Driven by rapid advancements in diagnostic technology and an increasing prevalence of cancer, the market is expected to expand at a robust compound annual growth rate (CAGR) of 21.7% over the next decade. By 2033, the market is forecast to reach a valuation of USD 10,938.6 million.
Liquid biopsy, a non-invasive diagnostic tool, is revolutionizing cancer detection by analyzing biomarkers in blood or other bodily fluids. This innovation provides early and accurate detection, enabling more personalized treatment plans for cancer patients. As healthcare providers and researchers continue to embrace this groundbreaking technology, the liquid biopsy market is expected to unlock significant growth opportunities.
Top Trends Impacting the Liquid Biopsy Market
- WHO, in 2020, reported around 10 million cancer-related deaths. Such a staggering rise in the incidence rate of different cancers strongly emphasizes the demand for convenient and precision cancer diagnostic tests for early detection.
- Governments of different economies with a rising cancer burden have pledged to support cancer research by offering sufficient funds for improved outcomes. For instance, according to the National Institute of Health (NIH), the National Cancer Institute was allocated US$ 119 million by the federal government in the United States in 2021.
- Researchers are continuously making new advancements in the biomarkers to detect and evaluate cancer by utilizing liquid biopsy. For instance, the development of new biomarkers for early cancer detection and subsequent treatment response.
Companies Operating in the Liquid Biopsy Market
- BIOCEPT, INC.
- Qiagen N.V.
- Trovagene, Inc
- Janssen Global Services, LLC
- MDxHealth SA
- Natera, Inc
- F. Hoffmann-La Roche Ltd
- Silicon Biosystems
- Pathway Genomics Corporation
- Sysmex Corporation
- Others
Access the Full Report
Key Segments Profiled in the Liquid Biopsy Industry Survey
By Biomarker Type:
- CTCs (Circulating Tumour Cells)
- ctNA (Circulating tumor Nucleic Acids)
- Exosomes
By Sample Type:
- Blood Liquid Biopsy
- Urine Liquid Biopsy
- Other (Plasma, Saliva, CSF) Liquid Biopsy
By Application Type:
- Liquid Biopsy for Lung Cancer
- Liquid Biopsy for Gastrointestinal Cancer
- Liquid Biopsy for Prostate Cancer
- Liquid Biopsy for Breast Cancer
- Liquid Biopsy for Colorectal Cancer
- Liquid Biopsy for Leukemia
By Region:
- North America
- Latin America
- Western Europe
- Eastern Europe
- Asia Pacific Excluding Japan
- Japan
- Middle East and Africa
Author By:
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube